Opicapone (Ongentys®). HTA ID: 20055

Assessment Status Rapid Review Complete
HTA ID 20055
Drug Opicapone
Brand Ongentys®
Indication As adjunctive therapy to levodopa and DOPA decarboxylase inhibitors (L-DOPA+DDCI) in adults with Parkinson’s disease and end-of-dose motor fluctuations in patients not stabilised on such combinations.
Assessment Process
Rapid review commissioned 14/12/2020
Rapid review completed 18/01/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends opicapone not be considered for reimbursement at the submitted price*.

 *This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations January 2022.